- Home
- RMMZ vs COYA Comparison
RMMZ vs COYA Comparison
Compare RMMZ & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$4.21
Company Overview
Basic Information| Metric | RMMZ | COYA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 102.7M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RMMZ | COYA |
|---|---|---|
| Price | $13.58 | $4.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.21 |
| AVG Volume (30 Days) | 34.1K | ★ 135.6K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $387.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $12.77 | $3.71 |
| 52 Week High | $15.29 | $7.55 |
Technical Indicators
Market Signals| Indicator | RMMZ | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 38.77 |
| Support Level | $12.84 | $3.89 |
| Resistance Level | $15.04 | $5.17 |
| Average True Range (ATR) | 0.22 | 0.28 |
| MACD | 0.10 | -0.08 |
| Stochastic Oscillator | 93.32 | 17.82 |
Price Performance
Historical Comparison RMMZ
COYA
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.